ReviewFrontiers in cardiovascular medicine2026
Machine learning approaches for risk prediction in aortic dissection: a systematic review and meta-analysis.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Centroid Regression for Preoperative Risk Assessment of Acute Type A Aortic Dissection Based on Multivariate Clinical Data.Journal of clinical medicine · 2026Article
- Multi-Output Machine Learning for Prediction of Postoperative Outcomes After Cardiac Surgery Using Patient Blood Management Biomarkers.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Aortic dissection (AD) is a life-threatening cardiovascular emergency with high morbidity and mortality. Accurate risk prediction is essential for timely intervention, yet traditional statistical models often fail to capture the complex, nonlinear interactions inherent in AD pathophysiology. In recent years, machine learning (ML) has emerged as a promising approach to improve prognostic accuracy. However, the overall performance, methodological quality, and clinical applicability of ML-based prediction models for AD have not been comprehensively evaluated. Objective: This systematic review and meta-analysis followed PRISMA, CHARMS, and TRIPOD guidelines and was registered with PROSPERO (CRD420251154262). Six major databases (PubMed, Web of Science, Cochrane Library, Embase, CNKI, Wanfang) were searched from inception to September 30, 2025. Studies developing or validating ML models for predicting adverse outcomes in AD were included. Data extraction adhered to CHARMS, and risk of bias was assessed using PROBAST. Meta-analysis synthesized C-statistics (AUC) using fixed- or random-effects models depending on heterogeneity. Subgroup, sensitivity, and publication bias analyses were performed. Results: Forty studies were included, covering outcomes such as early mortality, long-term mortality, acute kidney injury (AKI), neurological complications, gastrointestinal bleeding, mesenteric malperfusion, and composite adverse events. ML algorithms included random forest, SVM, XGBoost, LightGBM, neural networks, and ensemble approaches. The pooled C-statistic demonstrated excellent discriminative performance for early mortality (0.891, 95% CI: 0.854-0.927) and long-term mortality (0.847, 95% CI: 0.794-0.900), and strong performance for AKI prediction (0.825, 95% CI: 0.756-0.894). Many complication-specific models achieved AUCs above 0.90. However, these estimates must be interpreted with extreme caution. Significant heterogeneity was observed across analyses ( Conclusion: ML-based prediction models demonstrate strong potential for risk stratification in AD across multiple clinically relevant outcomes. However, current evidence does not justify their routine clinical implementation. The high reported performance metrics are likely optimistic estimates derived from methodologically weak studies. Future research should emphasize rigorous analytic frameworks, standardized outcome definitions, transparent reporting, and, most critically, multicenter external validation before these tools can be considered for real-world clinical utility. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251154262, identifier CRD420251154262.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.